AllCells Releases New Line of Bioservices

EMERYVILLE, Calif., Jan. 3, 2013 /PRNewswire/ -- AllCells LLC, a leading provider of healthy & diseased hematopoietic tissues and related services to the global life science industry is proud to announce the release of a new line of Bioservices. The CRO type of Bioservices will be focusing on drug discovery, preclinical research, drug toxicity assays, and other life science research applications. 

Immunoassays

• ELISA (single, multiplex)
• ELISpot
• Cell Based Assays
• Luminex Assays (single, multiplex)

Stem Cell Assays

• Hematopoietic Stem Cell Based Assays
• Colony Forming Assays (CFU assays)
  • CFU-M, CFU-GM, CFU-G, BFU-E
• Mesenchymal Stem Cell Based Assays
  • CFU-F, osteoblast, chondrocyte and adipocyte differentiation

 Flow Cytometry Services

• Immunophenotyping
• Intracellular and extracellular expression analysis
• CD34 Enumeration

Tissue Culture Services

• Proliferation Assays
• Toxicology Studies
• Cell Viability Assays

Protein Analysis

• Electrophoresis
• Western Blot
• Immunoprecipitation

Genotyping

• Mutation Analysis
• gDNA Extraction
• CD16 Genotyping
• HLA Typing Service

For a complete list and more in-depth descriptions, please refer to the AllCells 2013-2014 Product Catalog.

"The introduction of these CRO type of Bioservices provide essential components of hematological cell-based assays commonly used in the work-flow of drug development based research projects," commented Dr. Basha Stankovich, Manager of Bioservices.  Dr. Jack Zhai, VP of Sales & Marketing added, "These Bioservices offerings combine with our 20 years of experience in hematology, which provides our customers with a range of cell-based assays within the academia/non-profit market segment."

For more information about our Bioservices, please visit http://www.allcells.com/bioservices/. Full press release available here: http://www.allcells.com/blog/allcells-releases-new-line-of-bioservices/ .

About AllCells, LLC

AllCells, LLC is a global biotechnology company founded in 1998 to provide researchers with a reliable supply of biologically relevant, consistent quality primary cells that enable the advancement of scientific research in the areas of cell biology, oncology, virology, hematology, infectious disease and stem cell research. Unlike cell lines, which are typically mutated, transformed or immortalized, primary cells retain their original phenotypes hence better reflect in vivo morphology, metabolism and growth characteristics. These attributes are especially important for in vitro research applications where in vivo-like models are critically important. By partnering with AllCells, investigators can dramatically reduce time needed to isolate cells with guaranteed consistency thereby improving the efficiency, accuracy and relevance of their research studies. AllCells is fully certified in accordance with local, state and federal requirements.

SOURCE AllCells, LLC